Want to see ES:ATRY full AI Analyst Report?
ATRY Stock Chart & Stats
€2.53
€0.05(2.02%)
At close: 4:00 PM EDT
€2.53
€0.05(2.02%)
Day’s Range― - ―
52-Week Range€2.31 - €3.59
Previous CloseN/A
Volume7.64K
Average Volume (3M)83.73K
Market Cap
€197.16M
Enterprise Value€467.36
Total Cash (Recent Filing)€17.76M
Total Debt (Recent Filing)€257.87M
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Nov 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.32
Shares Outstanding76,014,190
10 Day Avg. Volume190,561
30 Day Avg. Volume83,732
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.47
Price to Sales (P/S)1.58
P/FCF Ratio-15.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.02
Revenue Forecast (FY)€183.14M
Bulls Say, Bears Say
Bulls Say
Business Model / Structural DemandAtrys focuses on radiation oncology and medical diagnostics paid through reimbursements and service contracts. That structural exposure to essential oncology care and contracted payments supports recurring revenue streams and patient volumes, making core demand less cyclical and more durable over months.
High Gross MarginsReported consistently strong gross profit across 2021–2024 indicates the core services generate healthy underlying margins. Strong gross margins provide a durable buffer against cost pressure and mean that, with disciplined operating cost control, the business has a clearer path to operational profitability than low-margin peers.
Manageable LeverageDebt has historically been moderate (generally below 1x equity), which preserves financial flexibility. Manageable leverage reduces immediate solvency risk and gives management time and capacity to address operational weaknesses or refinance needs without forcing a rapid deleveraging that could disrupt service delivery.
Bears Say
Persistent Operating LossesOperating losses across periods, culminating in a much larger 2025 loss, show the company has not converted gross profit into sustainable operating profitability. Ongoing deficits erode equity, limit reinvestment, and require recurring financing or structural cost reductions to avoid long-term viability issues.
Negative Free Cash FlowConsistent negative free cash flow and inconsistent operating cash flow indicate recurring cash burn. Reliance on external financing or balance-sheet moves to fund operations raises refinancing and liquidity risks, constrains capital allocation for growth, and shortens the runway for executing strategic fixes.
Revenue Volatility / Recent ContractionA sharp 2025 revenue decline following earlier growth underscores volatile demand or contract exposure. Revenue volatility undermines scale economics, makes cost recovery harder, complicates forecasting and payer negotiations, and raises the bar for achieving sustained margin and cash-flow recovery over the medium term.
Atrys Health SA News
ATRY FAQ
What was Atrys Health SA’s price range in the past 12 months?
Atrys Health SA lowest stock price was €2.31 and its highest was €3.59 in the past 12 months.
What is Atrys Health SA’s market cap?
Atrys Health SA’s market cap is €197.16M.
When is Atrys Health SA’s upcoming earnings report date?
Atrys Health SA’s upcoming earnings report date is Nov 13, 2026 which is in 86 days.
How were Atrys Health SA’s earnings last quarter?
Currently, no data Available
Is Atrys Health SA overvalued?
According to Wall Street analysts Atrys Health SA’s price is currently Overvalued.
Does Atrys Health SA pay dividends?
Atrys Health SA does not currently pay dividends.
What is Atrys Health SA’s EPS estimate?
Atrys Health SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Atrys Health SA have?
Atrys Health SA has 76,014,190 shares outstanding.
What happened to Atrys Health SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Atrys Health SA?
Currently, no hedge funds are holding shares in ES:ATRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Atrys Health SA
Atrys Health, S.A., a biomedical enterprise founded in 2007 and based in Madrid, Spain, specializes in providing a range of diagnostic services and medical treatments. Its diagnostic portfolio encompasses areas like pathology, hematology, molecular pathology, and genetics, supplemented by offerings such as diagnostic second opinions, a comprehensive test directory, and support for clinical trials and research & development. The company effectively utilizes telemedicine to deliver its expertise in medical specialties including radiology, cardiology, ophthalmology, and dermatology. Furthermore, Atrys Health administers radiotherapy and is engaged in the development of innovative therapeutic approaches and diagnostic instruments. The organization operated as Althia Health, S.L. before rebranding to Atrys Health, S.A. in May 2016.
Technical Analysis
Oryzon Genomics SA
―
Pharma Mar SA
―
1nKemia IUCT Group SA
―
PRIM, S.A.
―
Labiana Health SA
―